# Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression

> **NCT06977061** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Queling Liu** · enrollment: 30 (estimated)

## Conditions studied

- Gastric Neoplasm

## Interventions

- **DRUG:** Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT06977061
- **Lead sponsor:** Queling Liu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06977061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06977061, "Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06977061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*